BR112022014862A2 - THERAPEUTIC USES OF DULAGLUTIDE - Google Patents
THERAPEUTIC USES OF DULAGLUTIDEInfo
- Publication number
- BR112022014862A2 BR112022014862A2 BR112022014862A BR112022014862A BR112022014862A2 BR 112022014862 A2 BR112022014862 A2 BR 112022014862A2 BR 112022014862 A BR112022014862 A BR 112022014862A BR 112022014862 A BR112022014862 A BR 112022014862A BR 112022014862 A2 BR112022014862 A2 BR 112022014862A2
- Authority
- BR
- Brazil
- Prior art keywords
- dulaglutide
- patient
- therapeutic uses
- effective amount
- therapeutically effective
- Prior art date
Links
- 229960005175 dulaglutide Drugs 0.000 title abstract 4
- 108010005794 dulaglutide Proteins 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 3
- 230000006999 cognitive decline Effects 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
USOS TERAPÊUTICOS DE DULAGLUTIDA. A presente invenção refere-se a métodos para tratar, prevenir ou retardar transtornos relacionados à cognição, tais como declínio cognitivo, comprometimento cognitivo ou demência em um paciente. Especificamente o método compreende administrar dulaglutida em uma quantidade terapeuticamente eficaz ao paciente uma vez por semana. São divulgados ainda métodos para melhorar o controle glicêmico em um paciente com diabetes melito tipo 2, compreendendo administrar dulaglutida em uma quantidade terapeuticamente eficaz para reduzir o risco do paciente apresentar declínio cognitivo.THERAPEUTIC USES OF DULAGLUTIDE. The present invention relates to methods for treating, preventing or delaying cognition-related disorders such as cognitive decline, cognitive impairment or dementia in a patient. Specifically the method comprises administering dulaglutide in a therapeutically effective amount to the patient once a week. Further disclosed are methods for improving glycemic control in a patient with type 2 diabetes mellitus, comprising administering dulaglutide in a therapeutically effective amount to reduce the patient's risk of experiencing cognitive decline.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967790P | 2020-01-30 | 2020-01-30 | |
| PCT/US2021/014525 WO2021154591A1 (en) | 2020-01-30 | 2021-01-22 | Therapeutic uses of dulaglutide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014862A2 true BR112022014862A2 (en) | 2022-10-11 |
Family
ID=77078331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014862A BR112022014862A2 (en) | 2020-01-30 | 2021-01-22 | THERAPEUTIC USES OF DULAGLUTIDE |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230088005A1 (en) |
| EP (1) | EP4096704A4 (en) |
| JP (1) | JP2023513054A (en) |
| KR (1) | KR20220132606A (en) |
| CN (1) | CN114980917A (en) |
| AU (1) | AU2021213682A1 (en) |
| BR (1) | BR112022014862A2 (en) |
| CA (1) | CA3166573A1 (en) |
| IL (1) | IL295182A (en) |
| MX (1) | MX2022009383A (en) |
| WO (1) | WO2021154591A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190142905A1 (en) * | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| CR20200202A (en) * | 2017-11-21 | 2020-08-20 | Lilly Co Eli | Methods of using and compositions containing dulaglutide |
| BR112022007721A2 (en) * | 2019-11-06 | 2022-07-12 | Novo Nordisk As | METHOD FOR THE TREATMENT OF DEMENTIA |
-
2021
- 2021-01-22 WO PCT/US2021/014525 patent/WO2021154591A1/en active Application Filing
- 2021-01-22 CN CN202180012202.6A patent/CN114980917A/en active Pending
- 2021-01-22 BR BR112022014862A patent/BR112022014862A2/en unknown
- 2021-01-22 KR KR1020227029410A patent/KR20220132606A/en unknown
- 2021-01-22 JP JP2022546514A patent/JP2023513054A/en active Pending
- 2021-01-22 MX MX2022009383A patent/MX2022009383A/en unknown
- 2021-01-22 US US17/795,797 patent/US20230088005A1/en active Pending
- 2021-01-22 IL IL295182A patent/IL295182A/en unknown
- 2021-01-22 EP EP21748329.6A patent/EP4096704A4/en active Pending
- 2021-01-22 CA CA3166573A patent/CA3166573A1/en active Pending
- 2021-01-22 AU AU2021213682A patent/AU2021213682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114980917A (en) | 2022-08-30 |
| JP2023513054A (en) | 2023-03-30 |
| EP4096704A1 (en) | 2022-12-07 |
| IL295182A (en) | 2022-09-01 |
| EP4096704A4 (en) | 2024-01-31 |
| WO2021154591A1 (en) | 2021-08-05 |
| CA3166573A1 (en) | 2021-08-05 |
| MX2022009383A (en) | 2022-11-07 |
| KR20220132606A (en) | 2022-09-30 |
| US20230088005A1 (en) | 2023-03-23 |
| AU2021213682A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0417493B8 (en) | use of a botulinum toxin to treat skin disorders | |
| BRPI0417829A (en) | diabetes treatment compositions and processes | |
| MX2013004699A (en) | Pharmaceutical combinations for the treatment of metabolic disorders. | |
| ECSP088139A (en) | METHODS TO PREVENT AND TREAT METABOLIC AND NEW DISORDERS DERIVED FROM PIRAZOL-O-GLUCOSIDE | |
| MX2022001623A (en) | Methods of treating fabry disease in patients having a mutation in the gla gene. | |
| Kossoff et al. | Nonpharmacologic care for patients with L ennox‐G astaut syndrome: Ketogenic diets and vagus nerve stimulation | |
| BRPI0514397A (en) | 3-arylthioindole-2-carboxamide derivatives and analogues thereof as inhibitors of casein kinase epsilon | |
| BR112022013554A2 (en) | METHODS TO TREAT PEMPHIGUUS DISORDERS | |
| BR112022014862A2 (en) | THERAPEUTIC USES OF DULAGLUTIDE | |
| US11369619B2 (en) | Composition for curing migraine headaches | |
| BR112022011332A2 (en) | VECTOR OF RECOMBINANT ADENO-ASSOCIATED VIRUS, RECOMBINANT ADENO-ASSOCIATED VIRUS, AND, METHOD TO TREAT AN INDIVIDUAL WITH HUNTER'S SYNDROME | |
| Cuomo et al. | Effectiveness of light therapy as adjunctive treatment in bipolar depression: A pilot study | |
| Elahi et al. | High cervical epidural neurostimulation for post-traumatic headache management | |
| Alkhatib | Neurobiological and physiological aspects of disease: Brain as a key with multiple links, a new medical hypothesis | |
| Pesando et al. | Bilateral papilloedema in long term therapy with lithium carbonate | |
| BR112022003183A2 (en) | Uses of dpp-iv inhibitor and a combination of dpp-iv inhibitor and metformin, pharmaceutical composition and combination to delay loss of glycemic control | |
| MX2023003258A (en) | TREATMENT OF NF-κB-MEDIATED DISEASE. | |
| WO2021038500A3 (en) | Esketamine for the treatment of patients with major depressive disorder, including suicidality | |
| BR112022024728A2 (en) | COMPOUNDS AND METHODS FOR TREATMENT OF OPHTHALMOLOGICAL DISORDERS | |
| MX2021009383A (en) | Methods for treating symptoms and disorders associated with lysosomal storage diseases. | |
| WO2019066548A3 (en) | Pharmaceutical composition for prevention or treatment of heart failure | |
| JP4775940B2 (en) | Allodynia treatment, improvement, prevention agent | |
| US10960060B1 (en) | Treatment of cardiac arrhythmia using botulinum toxin | |
| Liu et al. | Extradural injections and manual repositioning of spine in treatment of megalgia caused by cervical spondylotic radiculopathy | |
| AR120666A1 (en) | COMBINATION THERAPY USING GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY |